China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel coronavirus fusion protein vaccine, V-01. The vaccine was first administered as a sequential booster shot in Guangdong on September 21. V-01 is being co-developed by Livzon subsidiary Zhuhai Livzon Monoclonal Antibodies Biotechnology Co., Ltd and the Institute of Biophysics from the Chinese Academy of Sciences.
Vaccine Development and Mechanism
V-01 utilizes the COVID-19 Spike protein (RBD) dimer as the subunit antigen and fuses biological adjuvants, including interferon and pan epitope, into the molecule. This unique design significantly enhances the level of virus-neutralizing antibodies and generates an effective cellular response. Previous clinical and real-world studies have demonstrated that V-01, as a sequential booster, has a good safety, tolerance, and immunogenicity profile.
Clinical Performance and Regulatory Milestones
V-01 has shown an absolute protection rate of over 60% and has proven effective in neutralizing the Omicron variant. The vaccine obtained emergency use authorization as a sequential booster shot in China on September 5. Livzon has also filed for marketing authorization in multiple countries and regions worldwide, highlighting its commitment to addressing the ongoing COVID-19 pandemic.-Fineline Info & Tech
